Effects of Sodium/Glucose Cotransporter 2 (SGLT2) Inhibitors and Combined SGLT1/2 Inhibitors on Cardiovascular, Metabolic, Renal, and Safety Outcomes in Patients with Diabetes: A Network Meta-Analysis of 111 Randomized Controlled Trials
ConclusionsIn patients with T2DM, compared with pure SGLT2 inhibitors, combined SGLT1/2 inhibitors demonstrated a lower risk of myocardial infarction and of stroke, but were associated with a higher risk of diarrhea and severe hypoglycemia.
Source: American Journal of Cardiovascular Drugs - Category: Cardiology Source Type: research
More News: Canagliflozin | Cardiology | Cardiovascular | Dapagliflozin | Databases & Libraries | Diabetes | Diabetes Mellitus | Diabetes Type 1 | Diabetes Type 2 | Empagliflozin | Endocrinology | Forxiga | Heart | Heart Attack | Invokana | Jardiance | SGLT2 Inhibitors | Sodium | Stroke